Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone antibiotic presented as a intravenous injection solution for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH USA supplies Moxifloxacin Krka as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone indicated for several serious bacterial infections.

Community‑acquired bacterial pneumonia: effective in eradicating the causative pathogens and improving clinical outcomes. Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation. Skin and soft tissue infections: provides rapid bacterial clearance and promotes healing. Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic organisms to resolve infection.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases. - Transient dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Hepatic failure: rare but potentially life‑threatening liver injury. - Peripheral neuropathy: persistent numbness or tingling in extremities.

When prescribing Moxifloxacin, clinicians should consider several safety measures.

Renal impairment: monitor renal function and adjust therapy as needed. QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. Concomitant corticosteroids: increased risk of tendon rupture; use with caution. Pregnancy and lactation: prescribe only if benefits outweigh potential risks. Tendon disorders: discontinue immediately if tendon pain, swelling, or rupture occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce moxifloxacin absorption. - Corticosteroids: increase risk of tendon rupture. - Warfarin: enhanced anticoagulant effect, may raise INR. - Strong CYP1A2 inhibitors (e.g., fluconazole): increase plasma concentrations. - QT‑prolonging agents (e.g., macrolides): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - NSAIDs: potential for central nervous system stimulation. - Theophylline: may raise serum theophylline levels. - Diabetes medications (e.g., insulin): possible alteration of glucose control. - Proton pump inhibitors: may modestly affect absorption. - Statins: increased risk of myopathy when combined.